A detailed history of Great West Life Assurance CO transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Great West Life Assurance CO holds 13,434 shares of DNLI stock, worth $329,133. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,434
Previous 13,434 -0.0%
Holding current value
$329,133
Previous $312,000 25.64%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$14.96 - $23.22 $55,501 - $86,146
3,710 Added 38.15%
13,434 $312,000
Q3 2023

Nov 14, 2023

BUY
$20.63 - $30.17 $111,402 - $162,918
5,400 Added 124.88%
9,724 $200,000
Q2 2023

Aug 10, 2023

SELL
$23.37 - $32.96 $7,431 - $10,481
-318 Reduced 6.85%
4,324 $128,000
Q3 2022

Nov 01, 2022

BUY
$25.97 - $38.53 $120,552 - $178,856
4,642 New
4,642 $142,000
Q2 2022

Aug 09, 2022

BUY
$20.88 - $35.19 $16,035 - $27,025
768 Added 19.82%
4,642 $137,000
Q1 2022

May 12, 2022

SELL
$29.0 - $47.27 $17,052 - $27,794
-588 Reduced 13.18%
3,874 $132,000
Q2 2021

Aug 11, 2021

SELL
$50.3 - $78.44 $22,182 - $34,592
-441 Reduced 8.99%
4,462 $350,000
Q1 2021

May 17, 2021

SELL
$53.8 - $81.53 $61,385 - $93,025
-1,141 Reduced 18.88%
4,903 $277,000
Q3 2020

Nov 17, 2020

SELL
$23.13 - $38.84 $198,039 - $332,548
-8,562 Reduced 58.62%
6,044 $216,000
Q3 2020

Nov 13, 2020

BUY
$23.13 - $38.84 $198,039 - $332,548
8,562 Added 141.66%
14,606 $523,000
Q4 2019

Feb 11, 2020

BUY
$14.4 - $19.99 $87,033 - $120,819
6,044 New
6,044 $105,000
Q3 2019

Oct 25, 2019

SELL
$15.32 - $21.92 $99,625 - $142,545
-6,503 Closed
0 $0
Q2 2019

Jul 31, 2019

SELL
$18.5 - $28.14 $16,668 - $25,354
-901 Reduced 12.17%
6,503 $0
Q3 2018

Nov 13, 2018

BUY
$12.46 - $21.74 $92,253 - $160,962
7,404 New
7,404 $161,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.29B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.